Scientific discoveries and milestones.


The Swedish mutation, which leads to early development of Alzheimer’s disease, was discovered in a Swedish family by Professor Lars Lannfelt


US patent application filed on the discovery of the Arctic mutation, and its propensity to form amyloid-beta oligomers/protofibrils a target for drug intervention


The discovery of the Arctic mutation was published. The Arctic mutation leads to increased production of amyloid-beta oligomers/protofibrils and early development of Alzheimer’s disease. This gave an insight into a new target for treatment of Alzheimer’s disease: amyloid-beta oligomers/protofibrils


BioArctic Neuroscience AB was founded by Lars Lannfelt and Pär Gellerfors


Karolinska Innovation AB invested in BioArctic (the asset was later transferred to Karolinska Development AB)

Concerning a transgenic mouse model (APPArcSwe), BioArctic filed two important patent applications concerning a transgenic mouse model and a concept patent for antibody treatment of Alzheimer’s disease


The drug candidate mAb158 (precursor to BAN2401) was isolated at Uppsala University, in Sweden

BioArctic and Eisai entered into a research collaboration concerning a disease modifying treatment for Alzheimer’s disease

BioArctic started research on Parkinson’s disease in collaboration with Uppsala University

Uppsala University Holding AB invested in BioArctic


BioArctic was located in own premises in Stockholm, in Sweden


BioArctic and Eisai entered into a license agreement concerning the antibody BAN2401 as a disease modifying treatment of Alzheimer’s disease as a result of the research collaboration agreement of 2005

The second US patent for Alzheimer’s disease was granted

BioArctic filed a patent application concerning the antibody BAN2401


BioArctic and Eisai entered into a second research collaboration concerning a back-up antibody to BAN2401


BioArctic signed an extension of the ongoing research collaboration with Eisai on immunotherapy for Alzheimer’s disease


BioArctic’s partner Eisai started a clinical Phase 2b study in the US concerning the drug candidate BAN2401 and the clinical development of BAN2401 was started in Japan


The clinical development of BAN2401 in Alzheimer’s disease was started in Europe

BioArctic’s partner Eisai entered into an agreement with Biogen concerning the continued development and commercialization of BAN2401 in Alzheimer’s disease


BioArctic and Eisai entered into a license agreement concerning BAN2401 Back-up, a follow-up project to BAN2401, and a third research collaboration agreement concerning a new disease modifying treatment for Alzheimer’s disease

BioArctic’s research program on Parkinson’s disease received grants from Swedish Vinnova and the EU’s research and development program Horizon2020 (Grant Agreement No. 697790)


The company’s name was changed from BioArctic Neuroscience AB to BioArctic AB

BioArctic entered into a collaboration agreement with AbbVie concerning research on Parkinson’s disease


The patent for BAN2401 backup was granted in the US

BioArctic received two grants from Swedish Vinnova for the company’s work with the quality management system and the commercial potential of antibody-based PET imaging

Trading in BioArctic’s B-shares commenced October 12th on Nasdaq Stockholm

BioArctic’s patent for its product candidate antibody BAN0805, for Parkinson’s disease, was granted in Europe


Positive BAN2401 Phase 2b clinical study results in early Alzheimer’s disease

Exclusive rights to develop the antibody AD1801 (in discovery) for Alzheimer’s disease

Expanded research collaboration with Uppsala University, Sweden, concerning antibody-based diagnostic imaging of the brain in Alzheimer patients

Research collaboration with Brain Biomarker Solutions in Gothenburg AB to develop new diagnostics for Alzheimer’s disease

Out-licensing of the portfolio of antibodies targeting alpha-synuclein to AbbVie for Parkinson’s disease and other potential indications

Granted concept patent in Europe for treatment strategy for disease-modifying treatment of Parkinson’s disease

Grant from EU’s Horizon 2020 for participation in research consortium for better diagnostic tools and biomarkers for Parkinson’s disease

Extended research collaboration with Uppsala University regarding new antibody technologies for increased passage across the blood-brain barrier (BBB-technology)


BAN2401 in Phase 3 for early Alzheimer’s disease

BioArctic initiated a research collaboration with Eisai aimed at further studying the unique profile of BAN2401

ABBV-0805 in Phase 1 for Parkinson’s disease

SC0806 closing since the results from the interim analysis of the Phase 1/2 study for complete spinal cord injury did not show any convincing effect


BioArctic’s drug candidate BAN2401 is assigned the international nonproprietary name lecanemab.

Alzheimer’s patients globally and in Sweden are included in the confirmatory Phase 3 study with lecanemab.

A new global Phase 3 program is initiated with lecanemab in preclinical asymptomatic Alzheimer’s disease.

Eisai presents promising new data from the open-label Phase 2b extension study with lecanemab.

BioArctic and the University of Oslo sign research agreements for further study of Apolipoprotein E as a target protein in Alzheimer’s disease.

BioArctic receives the 2020 Allbright Prize for its equality initiatives.


The FDA grants breakthrough therapy and fast track designation for lecanemab in Alzheimer’s disease.

Eisai initiates a rolling submission of the application to the FDA for market approval of lecanemab in early Alzheimer’s disease under an accelerated pathway.

Eisai conducts a Phase 1 study with subcutaneous administration for treatment with lecanemab.

BioArctic combines two early projects against Alzheimer’s disease, AD-BT2802 and AD-BT2803, with its blood-brain barrier technology.

BioArctic and Eisai present new data that strengthens earlier positive results for lecanemab at the AD/PD, AAIC and CTAD scientific congresses.

New data for ABBV-0805 in Parkinson’s disease is presented at the MDS congress, and preclinical data showing that ABBV-0805 selectively binds to soluble harmful aggregates of alpha-synuclein is published in Neurobiology of Disease.

BioArctic also announced that its ND3014 drug candidate targets the development of selective antibody drugs with the protein TDP-43 for the treatment of the rare neurodegenerative disease ALS.